SureTrader Advertisement Advertisement
Home > Boards > US Listed > Medical - Equipment >

Cytosorbents Corporation (CTSO)

Add CTSO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator The_Free_Nebula
Search This Board:
Last Post: 11/30/2015 4:08:55 PM - Followers: 175 - Board type: Free - Posts Today: 1
About CytoSorbents, CytoSorb, and HemoDefend

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. In 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, allowing it to be sold throughout the European Union (E.U.) under the CE Mark, to be used in clinical situations where cytokines are elevated. The goal of the CytoSorb® cytokine filter is to reduce "cytokine storm" in critically-ill patients that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. The CytoSorb® filter has demonstrated statistically significant reductions in mortality in septic patients at high risk of death in early studies and is now being sold in Germany, Austria and Switzerland for the treatment of critical care illnesses, with availability in other E.U. countries planned in the future, assuming adequate and timely funding, and continued positive results from clinical studies.

HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of the blood supply. The HemoDefend technology utilizes the Company's polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions.

CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, reduction of post-surgical complications in cardiac surgery, treatment of inflammatory and autoimmune disorders, radio-imaging contrast removal in imaging and interventional radiology procedures, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company's website:


CytoSorb® - A First-in-Class Cytokine Filter Approved in the European Union


CytoSorb® is a potentially breakthrough critical care immunotherapy that attempts to address one of the most challenging unmet medical needs in medicine…the ability to prevent or mitigate multiple organ failure - the leading cause of death in the intensive care unit (ICU) from any cause.

In response to life-threatening conditions such as sepsis and infection, trauma, serious burn injuries, severe lung injury, and pancreatitis, the body frequently overreacts and produces a massive excess of cytokines, or “cytokine storm”. Cytokines normally help the body cope with injury, but at these levels, cytokine storm is toxic to the body, driving severe inflammation and a cascade of pathophysiologic changes in the body that cause cell damage, organ failure and often death. It follows that reduction of cytokine storm may limit this cascade of events, thereby reducing the severity of illness, and helping patients recover and survive. Until recently, however, there were no effective ways to reduce cytokine storm broadly.

CytoSorb® is a first-in-class extracorporeal cytokine filter, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated. It is compatible with standard hemodialysis machines and blood pumps found in most hospitals. Blood is pumped out of the body, through the CytoSorb® cartridge that contains the company’s proprietary blood compatible porous polymer beads, and the “purified” blood is recirculated back to the patient. In a six hour period, a patient's entire blood volume can be treated approximately 20 times.

CytoSorb® is clinically proven to reduce cytokine storm in the company's multi-center, randomized, controlled European Sepsis Trial conducted in Germany. Treatment was safe and well-tolerated in more than 300 human treatments in very sick patients with the worst forms of sepsis and lung injury, and treatment has been safe in nearly 1,500 human treatments overall. Early data suggests that CytoSorb® can reduce organ injury and improve survival in patients at high risk of cytokine injury, particularly those patients with very high cytokine levels, and patients older than age 65.

CytoSorb® has now been used successfully in many conditions where deadly inflammation can lead to organ injury and failure. We are seeing strong interest in the following clinical applications:


There are more than 100 key opinion leaders in Germany, Austria, and Switzerland (our direct sales territories) who are either using or committed to using CytoSorb in clinical practice or clinical studies. More than 30 investigator-initiated studies in a diverse set of applications are being planned, with many already enrolling patients. In the United States, the U.S. Air Force is funding a 30-patient, FDA-approved randomized controlled human trauma pilot study.

As these other independent studies progress, CytoSorbents collaborates with Dr. John Kellum at the University of Pittsburgh Medical Center, and is sponsoring clinical studies in the area of severe sepsis and septic shock, the result of an overzealous immune response to a severe infection such as pneumonia or a ruptured appendix. Severe sepsis and septic shock are collectively a top ten cause of death worldwide, afflicting approximately 27 million people annually, killing approximately 1 in 3 patients despite the best medical care. CytoSorbents is conducting clinical trials in Europea and currently has an FDA-approved IDE application to run a small sepsis trial in the U.S.. The company will look to conduct a U.S. pivotal sepsis study in the future as a key step towards U.S. FDA approval.

Because of the versatility of CytoSorb®, there are many other potential applications of the technology outside of critical care medicine as well. In particular, CytoSorb® has been used many times intraoperatively during open heart surgery, where the heart must be stopped in order to operate on it, while the blood is pumped outside of the body by a heart-lung machine that oxygenates the blood and pumps it back to the rest of the body. This procedure can result in the production of inflammatory mediators such as cytokines, as well as hemolysis and the release of free hemoglobin into the blood. This can result in inflammation and post-operative complications such as failure to wean from mechanical ventilation and kidney failure. There are more than 1 million open heart surgeries each year in the U.S. and E.U. combined, with an addressable market of more than $1 billion for CytoSorb®.

Another application is in cancer immunotherapy. Cancer cachexia is a wasting condition that occurs in most cancers that leads to rapid uncontrolled weight loss, anorexia, and physical debilitation. Patients lose the physical reserve needed to tolerate treatment and fight the cancer. Because CytoSorb® can remove a broad range of cytokines and other inflammatory mediators that drive cancer cachexia, it may be very helpful in this condition. CytoSorbents is exploring this application, as well as the use of CytoSorb® as a primary cancer immunotherapy to kickstart the immune system to attack cancer, with researchers at the University of Pennsylvania School of Veterinary Medicine.

CytoSorb® is being sold for clinical use in the European Union and in countries outside of the European Union that accept European CE Mark approval such as India, Russia, Turkey and others. The total addressable market for CytoSorb® in critical care applications such as sepsis, burn injury, trauma, ARDS, pancreatitis and other diseases is estimated at $10-15 Billion in the U.S. and Europe alone.


From Shareholder's Letter

Goals for 2014

We have laid out an ambitious, yet potentially achievable, agenda for the next two years. Some of our highest priorities are:

  • Greater awareness of our story and technology through increased media exposure and improved investor relations
  • Revenue growth and increased product adoption in our direct sales territories
  • Distributor agreements for CytoSorb in Europe and elsewhere
  • Strategic partnerships for our pipeline products
  • Non-dilutive funding from grants and other programs
  • Commencement of a U.S. based trial
  • Clinical data and new clinical applications with data being presented at key scientific conferences
  • Improving liquidity and institutional sponsorship of our stock with potential up-listing to a national stock exchange

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTSO News: Current Report Filing (8-k) 04:52 PM
CTSO News: Current Report Filing (8-k) 11/13/2015 09:56:06 AM
CTSO News: CytoSorbents Accelerates Growth in Q3 2015 11/13/2015 08:00:00 AM
CTSO News: Quarterly Report (10-q) 11/13/2015 07:59:03 AM
CTSO News: CytoSorbents To Meet With Investors at Brean Capital Life Sciences Summit and Stifel 2015 Healthcare Conference 11/09/2015 09:19:00 AM
News News Alert: Current Report Filing (8-k) 11/30/2015 04:52:22 PM
#6174  Sticky Note From Yahoo MB-Updated Cytosorbents Overview andy55q 12/19/14 10:40:16 AM
#7385   reaching for the 200 DMA The_Free_Nebula 11/30/15 04:08:55 PM
#7384   86 PARTICIPATING CLINICAL CENTERS- Cytosorb Registry andy55q 11/26/15 03:43:37 PM
#7383   Another cardiac trial (from German Clinical Trials Register) andy55q 11/25/15 11:05:34 AM
#7382   NHS failures mean thousands suffer or die from andy55q 11/24/15 11:09:31 AM
#7381   Rank Status Study 1 Recruiting International Registry on the Use of the CytoS andy55q 11/23/15 05:51:42 PM
#7380   Who cares.....But im loaded again @ 6.50.... LOL. GLA SABAI 11/23/15 02:17:09 PM
#7379   Another New andy55q 11/20/15 01:49:13 PM
#7378   RESPONSE FROM DR. CHAN - FROM THE MESSAGE BOARD dah174174 11/20/15 09:09:00 AM
#7377   Damn thing cant hold a charge The_Free_Nebula 11/19/15 10:19:41 AM
#7376   GOOD REPORT BY ZACKS dah174174 11/17/15 07:41:25 PM
#7375   New on andy55q 11/17/15 11:55:51 AM
#7374   Just thinking of the typical govt run health systems... Murph1953 11/15/15 02:39:26 PM
#7373   lexusandolive..."Based on the information reported by Cytosorb Q3 Murph1953 11/14/15 10:32:42 AM
#7372   Invitation to the Meeting of the German Society andy55q 11/14/15 09:59:00 AM
#7371   Not 1 sale of Fresenius until now and SABAI 11/13/15 09:19:34 PM
#7370   Atleast my next holidays in April 2016 to SABAI 11/13/15 03:49:57 PM
#7369   glad i did.....its always the same.... SABAI 11/13/15 03:00:09 PM
#7368   snow- The progress was good. The guidance showed hopester 11/13/15 12:24:53 PM
#7367   The market seems to have expected better numbers. snow 11/13/15 09:39:28 AM
#7366   Quarterly Report just released- EXCELLENT hopester 11/13/15 09:28:00 AM
#7365   looking up again...consolidation necessary The_Free_Nebula 11/13/15 08:58:59 AM
#7364   Good information! I didn't realize that, but Milo1 11/12/15 08:00:59 PM
#7363   EAP Approval: Does SEC require disclosure? If so, andy55q 11/12/15 06:36:33 PM
#7362   New CytoSorb videos andy55q 11/12/15 05:03:29 PM
#7361   I hope that pr re 8000 was real. Murph1953 11/12/15 04:44:44 PM
#7360   lexus' BTW (correct if wrong) Murph1953 11/12/15 02:06:11 PM
#7359   Murph1953, Exactly. I'll take either. lexusandolive 11/12/15 12:52:51 PM
#7358   lexusandolive I went over you arith' 2 ways and Murph1953 11/12/15 12:04:22 PM
#7357   Through deductive reasoning Cytosorb should have big numbers lexusandolive 11/12/15 10:31:55 AM
#7356   I sold 50% of my 6.50 er shares SABAI 11/11/15 01:07:33 PM
#7355   Question for the board.......... Murph1953 11/09/15 12:59:53 PM
#7354   NEWS -- CytoSorbents To Meet With Investors at Paulness 11/09/15 09:32:50 AM
#7353   Yo Hope' Murph1953 11/04/15 12:22:02 AM
#7352   Murph53- As long as your're willing to wait hopester 11/03/15 07:01:43 PM
#7351   Hopester, I agree, however, I think AEMD has Murph1953 11/03/15 12:19:33 PM
#7350   murph1953 - CTSO has something moving. They've got hopester 10/30/15 03:29:45 PM
#7349   Look guys, the institutions, however behind the curve, Murph1953 10/29/15 04:31:33 PM
#7348   Chart and indicators shaping up nicely. hopester 10/28/15 01:09:27 PM
#7347   New processed this record on October 28, 2015 andy55q 10/28/15 10:39:57 AM
#7346   Still hanging on ... I expect one of The_Free_Nebula 10/27/15 09:21:53 AM
#7345   NEWS -- CytoSorbents To Advance HemoDefend™ Towards Commercialization Paulness 10/27/15 09:10:33 AM
#7344   CytoSorbents is awarded $1.5 mln from the National dah174174 10/27/15 08:42:51 AM
#7343   79 PARTICIPATING CLINICAL CENTERS- Cytosorb Registry andy55q 10/20/15 11:16:28 AM
#7342   Literature on CytoSorb® -Therapy and related topics-September 2015 andy55q 10/15/15 05:36:23 PM
#7341   CDRH’s vision is for U.S. patients to have andy55q 10/15/15 01:05:58 PM
#7340   Quick Question: Makenlight 10/15/15 09:00:40 AM
#7339   Wow, you have humor. Great! ;-) SABAI 10/13/15 11:42:16 AM
#7338   It could be the pork fried rice . Paulness 10/13/15 11:32:20 AM
#7337   From Yahoo MB andy55q 10/09/15 10:00:29 PM
#7336   My gut says Big explosion soon..... EAP .... SABAI 10/07/15 12:46:48 PM